9.48

8.36% -0.865

After Hours: 9.01 -0.47 -4.96%

Nyxoah SA (NYXH)

Overview News Price History Discussions Forecast

Nyxoah SA stock is currently priced at $9.48, with a 24-hour trading volume of 21,031. It has seen a -8.36% decreased in the last 24 hours and a -22.68% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $10.35 pivot point. If it approaches the $9.30 support level, significant changes may occur.

Previous Close:

$10.35

Open:

$10.21

24h Volume:

21,031

Market Cap:

$271.91M

Revenue:

$4.71M

Net Income/Loss:

$-46.77M

P/E Ratio:

-5.4147

EPS:

-1.7508

Net Cash Flow:

$-60.34M

1W Performance:

-10.69%

1M Performance:

-22.68%

6M Performance:

+68.68%

1Y Performance:

+8.72%

1D Range:

$9.01

$10.54

52W Range:

$4.00

$20.00

Nyxoah SA Stock (NYXH) Company Profile

Name

Nyxoah SA

Sector

Healthcare (1189)

Industry

Medical Instruments & Supplies (60)

Phone

32 1 045 90 75

Address

Rue Edouard Belin 12, Mont-Saint-Guibert

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NYXH's Discussions on Twitter

Nyxoah SA Stock (NYXH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-22	Initiated	Oppenheimer	Outperform
Apr-06-22	Initiated	Wolfe Research	Peer Perform
Dec-21-21	Resumed	Cantor Fitzgerald	Overweight
Jul-28-21	Initiated	Cantor Fitzgerald	Overweight

Nyxoah SA Stock (NYXH) Latest News

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

GlobeNewswire Inc.

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Benzinga

Informations sur le nombre total de droits de vote et d'actions

GlobeNewswire Inc.

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

GlobeNewswire Inc.

Nyxoah SA Stock (NYXH) Financials Data

Nyxoah SA (NYXH) Revenue 2024

NYXH reported a revenue (TTM) of $4.71 million for the quarter ending December 31, 2023, a +44.52% rise year-over-year.

Nyxoah SA (NYXH) Net Income 2024

NYXH net income (TTM) was -$46.77 million for the quarter ending December 31, 2023, a -42.94% decrease year-over-year.

Nyxoah SA (NYXH) Cash Flow 2024

NYXH recorded a free cash flow (TTM) of -$60.34 million for the quarter ending December 31, 2023, a -26.86% decrease year-over-year.

Nyxoah SA (NYXH) Earnings per Share 2024

NYXH earnings per share (TTM) was -$1.6792 for the quarter ending December 31, 2023, a -32.56% decline year-over-year.

Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.